What is new in September 2026 is a small set of listed weight-loss clinical research opportunities, not a verified national set of paid focus groups. The documented listings include Melbourne and Adelaide clinical studies, plus a U.S.
online opportunity with different payment and verification terms. These opportunities involve health screening, treatment exposure, visits, or overnight stays. Payment generally compensates participants for time and study commitments; it is not a reward for losing weight.
Official resources:
- Check eligibility on Focusgroupplacement’s official study page — Use this page to check the study’s participation requirements.
- Read the official guidance from Nucleusnetwork — Use this primary source to verify the official guidance.
Table of Contents
- What listings are documented?
- What are the Melbourne Indigo Study terms?
- How does the Adelaide study compare?
- What does the U.S. online listing offer?
- Which opportunity fits your situation?
- Frequently Asked Questions
What listings are documented?
The Nucleus Network and CMAX pages describe clinical research studies rather than conventional market-research focus groups. The available evidence does not establish a nationwide september 2026 program of paid weight-loss focus groups. The listings also differ sharply in location, commitment, and risk: Applicants should compare the full schedule and medical requirements, not payment figures alone.
- Melbourne: first-in-human oral-drug study, with payment up to $4,200.
- Adelaide: injectable obesity-treatment study, averaging $300–$400 per night for completers.
- United States: online listing advertising $50–$99 for a 12-week commitment.
What are the Melbourne Indigo Study terms?
Nucleus Network is recruiting Melbourne adults with obesity or overweight for the Indigo Study, a first-in-human investigation of an oral drug. The study begins on 19 September 2026 and offers remuneration of up to $4,200, according to Nucleus Network's Indigo Study listing. The commitment includes an in-clinic stay and roughly five follow-up visits.
The listed intakes run from 19–23 September, 27 September–1 October, and 29 September–3 October, with follow-up continuing through 29 October. The key warning is the study's first-in-human status. Nucleus Network says the medicine could cause unexpected, serious, or life-threatening side effects. The payment therefore compensates a monitored clinical commitment, not successful weight loss.
How does the Adelaide study compare?
CMAX's Adelaide Healthy Weight Study is testing a potential obesity treatment delivered by subcutaneous injection. Its listing says completers average $300–$400 per night, with partial payment available during the study; see CMAX's Balanced Scale Study page. The study limits eligibility to generally healthy adults aged 18–65 with a BMI of 25–35 kg/m².
Applicants must also have no significant allergies or health conditions and agree to adequate contraception. The September schedule requires eight nights and 11 visits, beginning 9 September and continuing through 5 November 2026. A per-night figure can look attractive, but the total time away and repeated visits are central parts of the decision.
What does the U.S. online listing offer?
Focus Group Placement lists a nationwide U.S. opportunity for adults aged 40–70. The page, posted 18 August 2026, accepts applications through 18 September 2026 and advertises $50–$99 for a 12-week weight-loss research commitment.
Screening determines whether an applicant is contacted for enrollment. The listing does not identify the actual research sponsor or provide a trial-registry record, so its "clinical trial" description and payment range require independent confirmation. Before submitting health information, applicants should:.
- Ask who legally sponsors and conducts the study.
- Request the study's official consent information.
- Confirm the payment schedule and conditions.
- Verify the study through an independent official source.
- Avoid treating screening as guaranteed enrollment.
Which opportunity fits your situation?
The Melbourne listing may suit someone who can manage an intensive clinic stay and follow-up visits, but its first-in-human warning demands careful risk review. The Adelaide option has a longer calendar span and repeated visits, even though payment is described by night. The U.S.
listing appears less specific about its sponsor and study documentation. That uncertainty matters more than its advertised payment because applicants may share sensitive health information before knowing who operates the research. A practical comparison should record the location, age and BMI rules, treatment type, overnight requirements, visit count, payment conditions, safety disclosures, and sponsor identity. If any of those details remain unclear, pause before applying.
Frequently Asked Questions
Are these ordinary paid focus groups?
The documented Melbourne and Adelaide opportunities are clinical research studies, not conventional opinion-based focus groups.
Does payment depend on losing weight?
No. The listed payments compensate participants for study participation, visits, clinic stays, or overnight commitments.
Is the U.S. listing fully verified?
Its sponsor and trial-registry record are not identified on the listing, so applicants should independently confirm those details first.
You Might Also Like
- What Is New With Vegan Paid Focus Group Studies in September 2026? Latest study listings and sponsor terms and Key Takeaways
- What Is New With Laundry Paid Focus Group Studies in September 2026? Latest study listings and sponsor terms and Key Takeaways
- What Is New With LGBTQ Paid Focus Group Studies in September 2026? Latest study listings and sponsor terms and Key Takeaways
